Assessing Ocular Surface Changes After Changing Glaucoma Medications

Assessing Changes at the Ocular Surface Following the Switch From Xalatan to Travatan Z.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00554411

Enrollment

Registered

2007-11-06

Start date

2007-11-30

Completion date

2011-08-31

Last updated

2017-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Monotherapy With Xalatan From 1 to 18 Months, Ocular Surface Disease

Keywords

Travatan Z, glaucoma, tear film break up time

Brief summary

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Detailed description

Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* on Xalatan monotherapy from 1 to 18 months * 18 years of age or older * has been diagnosed with ocular surface disease

Exclusion criteria

* special populations such as children, pregnant females, prisoners, etc.

Design outcomes

Primary

Measure	Time frame
Change in Signs and Symptoms of Ocular Surface Disease	6 months

Countries

United States

Outcome results